Thomas Zoller

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7083812/publications.pdf

Version: 2024-02-01

36	1,540	331259	360668
papers	citations	21	35
		h-index	g-index

41	41	41	2409
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: An observational longitudinal study over 12 months. Respiratory Medicine, 2022, 191, 106709.	1.3	63
2	Symptoms and functional limitations related to respiratory health and carbon monoxide poisoning in Tanzania: a cross sectional study. Environmental Health, 2022, 21, 38.	1.7	1
3	Characterization of antimicrobial use and co-infections among hospitalized patients with COVID-19: a prospective observational cohort study. Infection, 2022, 50, 1441-1452.	2.3	10
4	Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study. Infection, 2021, 49, 703-714.	2.3	27
5	Iron homeostasis during anemia of inflammation: a prospective study of patients with tuberculosis. Blood, 2021, 138, 1293-1303.	0.6	20
6	Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study. Clinical Microbiology and Infection, 2021, 27, 1520.e7-1520.e10.	2.8	13
7	A time-resolved proteomic and prognostic map of COVID-19. Cell Systems, 2021, 12, 780-794.e7.	2.9	125
8	Long-term health sequelae and quality of life at least 6Âmonths after infection with SARS-CoV-2: design and rationale of the COVIDOM-study as part of the NAPKON population-based cohort platform (POP). Infection, 2021, 49, 1277-1287.	2.3	24
9	A longitudinal study on symptom duration and 60-day clinical course in non-hospitalised COVID-19 cases in Berlin, Germany, March to May, 2020. Eurosurveillance, 2021, 26, .	3.9	5
10	Outpatient treatment of imported uncomplicated Plasmodium falciparum malaria: results from a survey among TropNet and GeoSentinel experts for tropical medicine. Journal of Travel Medicine, 2020, 27, .	1.4	1
11	Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19). Infection, 2020, 48, 619-626.	2.3	79
12	Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses. Frontiers in Immunology, 2020, 11, 628971.	2.2	51
13	â€œWe have already heard that the treatment doesn't do anything, so why should we take it?â€: A mixed method perspective on Chagas disease knowledge, attitudes, prevention, and treatment behaviour in the Bolivian Chaco. PLoS Neglected Tropical Diseases, 2020, 14, e0008752.	1.3	5
14	Intravenous Artesunate for Imported Severe Malaria in Children Treated in Four Tertiary Care Centers in Germany. Pediatric Infectious Disease Journal, 2019, 38, e295-e300.	1.1	7
15	Chronic airflow obstruction in Tanzania â€“ a cross-sectional study. BMC Pulmonary Medicine, 2018, 18, 11.	0.8	6
16	Severe malaria in Europe: an 8-year multi-centre observational study. Malaria Journal, 2017, 16, 57.	0.8	57
17	Sentinel surveillance of imported dengue via travellers to Europe 2012 to 2014: TropNet data from the DengueTools Research Initiative. Eurosurveillance, 2017, 22, .	3.9	46
18	Schistosomiasis in European Travelers and Migrants: Analysis of 14 Years TropNet Surveillance Data. American Journal of Tropical Medicine and Hygiene, 2017, 97, 567-574.	0.6	69

#	Article	IF	Citations
19	Hemolysis after Oral Artemisinin Combination Therapy for UncomplicatedPlasmodium falciparumMalaria. Emerging Infectious Diseases, 2016, 22, 1381-1386.	2.0	39
20	Human isotypeâ€dependent inhibitory antibody responses against Mycobacterium tuberculosis. EMBO Molecular Medicine, 2016, 8, 1325-1339.	3.3	127
21	Reply to Jaureguiberry et al. Clinical Infectious Diseases, 2016, 62, 271-271.	2.9	2
22	Intravenous Artesunate Reduces Parasite Clearance Time, Duration of Intensive Care, and Hospital Treatment in Patients With Severe Malaria in Europe: The TropNet Severe Malaria Study: Figure 1.. Clinical Infectious Diseases, 2015, 61, 1441-1444.	2.9	38
23	The revised dengue fever classification in German travelers: clinical manifestations and indicators for severe disease. Infection, 2015, 43, 21-28.	2.3	14
24	Epidemiology of Chagas disease in Europe: many calculations, little knowledge. Clinical Research in Cardiology, 2014, 103, 1-10.	1.5	66
25	Methaemoglobin and COHb in patients with malaria. Malaria Journal, 2014, 13, 285.	0.8	6
26	Human African trypanosomiasis with 7-year incubation period: Clinical, laboratory and neuroimaging findings. Parasitology International, 2014, 63, 557-560.	0.6	20
27	Intravenous Artesunate for Severe Malaria in Travelers, Europe. Emerging Infectious Diseases, 2011, 17, 771-777.	2.0	109
28	Malaria transmission in non-endemic areas: case report, review of the literature and implications for public health management. Malaria Journal, 2009, 8, 71.	0.8	38
29	Analysis of risk factors for T. brucei rhodesiensesleeping sickness within villages in south-east Uganda. BMC Infectious Diseases, 2008, 8, 88.	1.3	23
30	Treatment of Acute Uncomplicated Falciparum Malaria with Artemether-Lumefantrine in Non-immune Populations: A Safety, Efficacy, and Pharmacokinetic Study. American Journal of Tropical Medicine and Hygiene, 2008, 78, 241-247.	0.6	87
31	Imported leishmaniasis in Germany 2001â€“2004: data of the SIMPID surveillance network. European Journal of Clinical Microbiology and Infectious Diseases, 2005, 24, 471-476.	1.3	46
32	Epidemiology and clinical features of vivax malaria imported to Europe: sentinel surveillance data from TropNetEurop. Malaria Journal, 2004, 3, 5.	0.8	79
33	Comparison of three antigen detection tests for diagnosis and follow-up of falciparum malaria in travellers returning to Berlin, Germany. Parasitology Research, 2003, 89, 354-357.	0.6	47
34	Sensitivity of P. vivax rapid antigen detection tests and possible implications for self-diagnostic use. Travel Medicine and Infectious Disease, 2003, 1, 119-122.	1.5	12
35	Age as a Risk Factor for Severe Manifestations and Fatal Outcome of Falciparum Malaria in European Patients: Observations from TropNetEurop and SIMPID Surveillance Data. Clinical Infectious Diseases, 2003, 36, 990-995.	2.9	93
36	Rapid Immunochromatographic Malarial Antigen Detection Unreliable for Detecting Plasmodium malariae and Plasmodium ovale. European Journal of Clinical Microbiology and Infectious Diseases, 2002, 21, 818-820.	1.3	50